Sepsis Solution Accelerate Diagnostics offers a rapid phenotypic antibiotic susceptibility system and BC kit that delivers results in approximately 7 hours from positive blood cultures, enabling faster optimization of antibiotic therapy for sepsis patients and potential expansions into hospital ICU and emergency department workflows.

Time to Action External studies show the platform provides results 1–2 days faster than traditional methods, presenting a clear value proposition for hospitals facing antimicrobial stewardship pressures and those seeking to reduce length of stay and improve patient outcomes.

Clinical Adoption Target high-volume tertiary and teaching hospitals with dedicated infectious disease and microbiology departments where rapid susceptibility data can substantially impact treatment protocols and antibiotic stewardship programs.

Financial Scale Current revenue range and modest funding suggest opportunities to upsell broader deployment within mid-sized to large health systems and to pursue co-investment or partnerships with regional distributors to accelerate adoption.

Strategic Partnerships Leverage collaboration potential with hospital procurement, IT for data integration, and clinical education programs; emphasize compatibility with existing lab workflows and potential for integration with EHR systems to streamline reporting and decision support.